I think we need to be mindful though that Qbrexza didn't sell in Japan previously, which is supposed to be BOT's closest competitor in the US.
Also, Qbrexza only sold $25m in the US last FY, so it would seem that even though Ecclock did well in Japan, it does seem BOT are expecting quite a take-up of SB in the US. I'm not sure their $100m is realistic. Don't get me wrong, I would love it to be $100m turnover within a year, but I expect that is years and years down the track.
Then again, maybe Qbrexza is an absolutely crap product in the hyperhidrosis world and we'll see SB sold at record levels.
Price predictions, page-58
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 36.0¢ | $3.051M | 8.277M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 465836 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 301865 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |